| Revenue growth | H1 revenue rose 31% YoY to ₹302.9cr; Q2 rose 15%. |
|---|---|
| Margins | EBITDA margins normalized to 38% after exceptional low raw material gains. |
| Demand visibility | Strong visibility in infant nutrition and battery materials; US recovering. |
| Management confidence | Confident, focusing on high-barrier certifications like USFDA and CEP. |
Growth
H1 revenue grew 31% YoY to ₹302.9cr; PAT increased to ₹78cr. Growth is diversifying via the NSS Ireland acquisition.
Outlook
Targeting 100,000 MT capacity in Dahej by FY28. Normalizing inventory to 140-150 days by mid-term.
Risks
High working capital days (195) and US tariff uncertainty affecting 50% of US business are concerns.
Earnings Call filed with NSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,164.90
- Market cap
- ₹13,157 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.0×Sector 50.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.